Literature DB >> 12396478

The effect of high dose digoxin on cytokines in healthy dogs.

Haluk Dülger1, Mehmet Ramazan Sekeroğlu, Beyhan Eryonucu, Tevfik Noyan, Süleyman Alici.   

Abstract

BACKGROUND: Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta are pro-inflammatory cytokines, causing myocardial dysfunction and a negative inotropic effect. The drugs used to treat heart failure affect the production of cytokines. Digoxin, on which this study was focused, is one of the drugs for the treatment of heart failure. AIM: The present study was designed to examine the early effects of high doses of digoxin on the production of cytokines in healthy dogs.
METHODS: Digoxin was given parenterally to dogs at 0.15 mg/kg. IL-1beta and TNF-alpha production and levels of digoxin in the serum were measured 0, 12, 24, 48, and 72 h following administration of digoxin.
RESULTS: As the levels of serum digoxin taken at 12, 24, 48, and 72 h of administration were considered significantly high compared with preceding values (p < 0.001), no notable change in serum IL-1beta and TNF-alpha levels was observed.
CONCLUSIONS: These results suggest that high doses of digoxin do not cause a significant cytokine production in heart muscle in the early phase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396478      PMCID: PMC1781670          DOI: 10.1080/096293502900000122

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  13 in total

1.  Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain.

Authors:  A Matsumori; K Ono; R Nishio; H Igata; T Shioi; S Matsui; Y Furukawa; A Iwasaki; Y Nose; S Sasayama
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.

Authors:  T Kubota; C F McTiernan; C S Frye; S E Slawson; B H Lemster; A P Koretsky; A J Demetris; A M Feldman
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

3.  Tumor necrosis factor-alpha and cardiomyopathy.

Authors:  M R Bristow
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

4.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

5.  Tumor necrosis factor-alpha serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure.

Authors:  J T Parissis; K F Venetsanou; D G Mentzikof; N G Ziras; C G Kefalas; S M Karas
Journal:  Scand Cardiovasc J       Date:  1999       Impact factor: 1.589

6.  High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity.

Authors:  A Matsumori; H Igata; K Ono; A Iwasaki; T Miyamoto; R Nishio; S Sasayama
Journal:  Jpn Circ J       Date:  1999-12

7.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.

Authors:  B F Uretsky; J B Young; F E Shahidi; L G Yellen; M C Harrison; M K Jolly
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

8.  Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart.

Authors:  T Yokoyama; L Vaca; R D Rossen; W Durante; P Hazarika; D L Mann
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Interleukin-1 beta modulates myocardial contraction via dexamethasone sensitive production of nitric oxide.

Authors:  H G Evans; M J Lewis; A M Shah
Journal:  Cardiovasc Res       Date:  1993-08       Impact factor: 10.787

10.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura.

Authors:  E Girardin; G E Grau; J M Dayer; P Roux-Lombard; P H Lambert
Journal:  N Engl J Med       Date:  1988-08-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.